Teva Pharmaceutical Industries (TEVA) has begun trading its ordinary shares directly on the New York Stock Exchange, marking a significant milestone for the global drugmaker.
The move represents a key step in Teva’s broader strategic pivot toward growth, as the company works to reposition itself within the competitive pharmaceutical landscape.
Teva is one of the world’s largest generic drug manufacturers, with a significant presence across both established and emerging markets globally.
The company has been executing a multi-year turnaround strategy aimed at reducing its substantial debt load while simultaneously investing in innovative new therapies.
Trading ordinary shares directly on the NYSE gives Teva greater visibility and accessibility among institutional and retail investors based in the United States.
Previously, Teva’s shares were traded on the NYSE through American Depositary Receipts, a common structure used by foreign-listed companies seeking access to US capital markets.
The transition to direct ordinary share trading is seen as a vote of confidence in the company’s financial stability and its long-term growth ambitions.
Teva has been focusing on its innovative medicines portfolio, including treatments in neuroscience and oncology, as part of its effort to diversify beyond generic drugs.
The company’s leadership has consistently emphasised the importance of this strategic pivot in restoring shareholder value following years of financial difficulty linked to debt and litigation costs.
Listing ordinary shares directly on one of the world’s most prominent stock exchanges positions Teva to attract a broader and more diverse base of long-term investors.
The NYSE listing milestone comes as Teva continues to navigate a complex global environment, including pricing pressures in the generics market and ongoing legal settlements.
Investors and analysts will be watching closely to see whether the direct listing structure translates into improved liquidity and stronger share price performance for TEVA going forward.